KIBBUTZ GALED, Israel, Sept. 18, 2019 /PRNewswire/ — Biogal Galed Labs, a global leader of veterinary diagnostic solutions, has announced the commercialization of the new CombCam, an automated reading device for Biogal’s VacciCheck and ImmunoComb kits.
This will make the interpretation of VacciCheck and ImmunoComb easier, less cumbersome, faster, digitalized and more accurate, says Amos Gershony, Biogal’s CEO.
This user friendly, add on technology, will greatly assist veterinarians in the vet clinic/ vet lab setting.
CombCam now offers the following benefits:
The CombCam is available for all of Biogal’s for Canine and Feline VacciCheck/ImmunoComb kits.
CLICK HERE for the official CombCam How to Use Video.
About Biogal-Galed Labs:
Biogal was established in 1986. Biogal’s various veterinary diagnostic products are available in over 35 countries.
Biogal developed the patented ImmunoComb, VacciCheck and PCRun technologies for the detection of pet infectious diseases.
Please visit www.biogal.com for more information.
For more information, contact:
Lenny Small
VP Marketing
Biogal, Galed Labs Acs Ltd.
Kibbutz Galed, 1924000, Israel
Phone: +972(0)4-9898605
len@biogal.co.il
View original content to download multimedia:http://www.prnewswire.com/news-releases/biogal-galed-labs-launches-combcam-an-automated-reading-device-for-biogals-vaccicheck-and-immunocomb-kits-300920779.html
SOURCE Biogal Galed Labs
* Efficacy, safety, and cost-effectiveness of Thermobalancing therapy and Dr Allen's Devices were showcased at…
FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report…
PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…
Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators Einstein A young and…
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…
TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)…